References
- American Cancer Society. Key Statistics for Cervical Cancer; 2023. Available from: https://www.cancer.org/cancer/types/cervical-cancer/about/key-statistics.html
- World Health Organization. Cervical Cancer. Available from: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer
- Duranti S, Pietragalla A, Daniele G, et al. Role of immune checkpoint inhibitors in cervical cancer: From preclinical to clinical data. Cancers (Basel). 2021;13(9):2089. doi: 10.3390/cancers13092089
- Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res. 2017;27(1):59–73. doi: 10.1038/cr.2016.153
- Ferrall L, Lin KY, Roden RBS, et al. Cervical cancer immunotherapy: facts and hopes. Clin Cancer Res. 2021;27(18):4953–4973. doi: 10.1158/1078-0432.CCR-20-2833
- Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 2015;27(1):39–46. doi: 10.1093/intimm/dxu095
- Frenel JS, Le Tourneau C, O’Neil B, et al. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: results from the phase ib KEYNOTE-028 trial. J Clin Oncol. 2017;35(36):4035–4041. doi: 10.1200/JCO.2017.74.5471
- Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37(17):1470–1478. doi: 10.1200/JCO.18.01265
- Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021 Nov 11;385(20):1856–1867. doi: 10.1056/NEJMoa2112435
- Santin AD, Deng W, Frumovitz M, et al. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol. 2020;157(1):161–166. doi: 10.1016/j.ygyno.2019.12.034
- Wendel Naumann R, Hollebecque A, Meyer T, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial. J Clin Oncol. 2019;37(31):2825–2834. doi: 10.1200/JCO.19.00739
- O’Malley DM, Neffa M, Monk BJ, et al. Dual PD-1 and CTLA-4 checkpoint blockade using Balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study. J Clin Oncol. 2022;40(7):762–771. doi: 10.1200/JCO.21.02067
- Lan C, Shen J, Wang Y, et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial. J Clin Oncol. 2020;38(34):4095–4106. doi: 10.1200/JCO.20.01920
- National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Cervical Cancer V 12024. 2023 Sep.
- Tewari KS, Monk BJ, Vergote I, et al. Survival with cemiplimab in recurrent cervical cancer. N Engl J Med. 2022;386(6):544–555. doi: 10.1056/NEJMoa2112187
- Merck announces phase 3 keynote-a18 trial met primary endpoint of progression-free survival (PFS) in patients with newly diagnosed high-risk locally advanced cervical cancer. 2023. Available from: https://www.merck.com/news/merck-announces-phase-3-keynote-a18-trial-met-primary-endpoint-of-progression-free-survival-pfs-in-patients-with-newly-diagnosed-high-risk-locally-advanced-cervical-cancer/
- Gennigens C, De Cuypere M, Hermesse J, et al. Optimal treatment in locally advanced cervical cancer. Expert Rev Anticancer Ther. 2021;21(6):657–671. doi: 10.1080/14737140.2021.1879646